Navigation Links
Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with Isentress
Date:8/26/2008

Most Surveyed MCO Pharmacy Directors Do Not Place Cost Control Measures on Branded Antiretroviral Drugs, According to a New Report from Decision

Resources

WALTHAM, Mass., Aug. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the expansion of labeling for Merck's Isentress to include use in treatment naive patients will significantly impact sales of the drug for HIV treatment as half of surveyed physicians expect to replace between six percent and 15 percent of their prescriptions for Bristol-Myers Squibb's Sustiva with Isentress. In 2007, 17 percent of first-line patients were treated with Sustiva, according to surveyed physicians.

The new Physician & Payer Forum primary market research report entitled Novel HIV Therapies: Physician and Payer Perspective on Recently Launched and Emerging Antiretrovirals finds that surveyed infectious disease specialists estimate that they will prescribe Isentress to more than 11 percent of their first-line patients if the drug is indicated for this patient population. Additionally, the report finds that most surveyed managed care organizations' (MCO) pharmacy directors do not place cost controls on many of the branded antiretroviral products that are covered in their private health plans. As a result, most antiretroviral drugs -- including Isentress and Sustiva -- will not be subjected to new cost control measures over the next 12 months, according to more than 80 percent of MCO pharmacy directors surveyed.

The report also finds that, in order to compete more effectively with other antiretroviral drugs, surveyed physicians indicate that drugs in the CCR5 antagonist class will need to overcome hurdles associated with the medically necessary test that is used to determine patient eligibility for CCR5 antagonist drug treatment. Physicians consider the prerequisite co-receptor tropism test for HIV patients to be a critical deterrent to prescribing CCR5 antagonist drugs.

"It is highly likely that all subsequent members of the CCR5 antagonist drug class will necessitate a tropism test prior to prescribing," said Sylvia Eash, Ph.D., analyst at Decision Resources. "To expand the use of their drugs and overcome this substantial hurdle to wider uptake, marketers of CCR5 antagonist drugs should actively support the development of a low cost test that delivers fast and accurate results."

Novel HIV Therapies: Physician and Payer Perspective on Recently Launched and Emerging Antiretrovirals is based on a U.S. survey of 103 infectious disease specialists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
2. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
3. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
4. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
5. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
6. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
7. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
8. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
9. Hot Information for Physicians Treating Vasomotor Symptoms During the Menopausal Transition
10. Off-Label Stent Use: How Important Are FDA Approvals to Physicians?
11. More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... , ... Kablooe Design, a leading provider of product design and development services ... the business. “We have worked hard to build long-term relationships,” says President and CEO, ... honor of serving their product design and development needs through the years.” , Kablooe ...
(Date:5/19/2016)... , May 19, 2016 ... will fully recover given the relentless pressures in pricing ... sure in the investors circle though - numerous opportunities ... Ahead of today,s session, ActiveWallSt.com,s presents four names in ... ), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE ), ...
(Date:5/18/2016)... ... May 18, 2016 , ... ... Summer Camp at The University of Toledo. This two-day camp will take place ... to explore the field of pharmaceutical sciences in preparation for a university academic ...
(Date:5/18/2016)... ... May 18, 2016 , ... Ryan Benton was diagnosed with Duchenne ... the late teens to early twenties. DMD is a relatively common progressive genetic disorder, ... of 22, Benton’s condition was critical. He met with the founder of the ...
Breaking Biology Technology:
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
(Date:3/15/2016)... 15, 2016 Yissum Research Development Company ... company of the Hebrew University, announced today the formation ... technology of various human biological indicators. Neteera Technologies has ... from private investors. ... detection of electromagnetic emissions from sweat ducts, enables reliable ...
Breaking Biology News(10 mins):